ANKRD33B-AS1

Across TCGA pan-cancer cohorts, ANKRD33B-AS1 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated ANKRD33B-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANKRD33B-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD33B-AS1 expression acts as an unfavorable survival marker, although some lineages such as ESCA and LAML show a favorable association.

LIHC, LUAD, and UCEC are the cancer types where ANKRD33B-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.152	0.706	<.001	51	view →
LUAD	OS	Tertile	IV	0.388	0.753	.004	36	view →
UCEC	DFS	Tertile	All	0.839	0.906	.001	36	view →
KIRP	DFS	Quartile	IV	0.115	0.580	.004	24	view →
ESCA	OS	Median	II,III,IV	0.632	0.466	.015	22	view →
LAML	DFS	Tertile	All	0.588	0.342	.002	22	view →
SKCM	OS	Tertile	III,IV	0.584	0.845	.008	21	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
PCPG	DFS	Tertile	All	0.088	0.846	.006	9	view →
DLBC	DFS	Median	All	0.622	1.000	.014	8	view →
OV	DFS	Quartile	III,IV	0.463	0.544	.033	8	view →
KIRC	DFS	Quartile	All	0.908	0.848	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

ANKRD33B-AS1–LIHC (OS)

Open the LIHC breakdown →